TAZ mediates enhancer reprogramming blocks neuronal differentiation in glioma stem-like cells

Area of Science:

• Neuro-oncology
• Cancer Stem Cell Biology
• Transcriptional Regulation

Background:

• Malignant gliomas, including glioblastomas, harbor glioma stem-like cells (GSCs) that drive tumor propagation.
• Targeting GSCs via non-cytotoxic differentiation is a promising therapeutic strategy but has faced challenges.
• The role of transcriptional coactivator with PDZ-binding motif (TAZ) in GSC hierarchy and differentiation remains unclear.

Purpose of the Study:

• To investigate the role of TAZ in regulating GSC hierarchy and neuronal differentiation.
• To identify molecular mechanisms by which TAZ influences GSC fate.
• To explore TAZ inhibition as a potential non-cytotoxic therapeutic strategy for malignant gliomas.

Main Methods:

• Integrated in silico, in vitro, and in vivo approaches.
• Analysis of TAZ expression and its correlation with master neuronal transcription factors (TFs).
• Investigated the impact of TAZ/YAP modulation on GSC differentiation and enhancer landscape, including the role of histone deacetylase 1 (HDAC1).

Main Results:

• TAZ was found to inhibit the neuronal lineage pathway in gliomas and GSCs.
• TAZ overexpression disrupted neuronal differentiation by altering the enhancer landscape and downregulating key neurogenesis TFs (e.g., OLIG2, ASCL1).
• Knockdown of TAZ and YAP induced aberrant neuronal differentiation, with effects mediated by HDAC1.

Conclusions:

• TAZ plays a critical role in suppressing neuronal differentiation in GSCs.
• Blocking TAZ/histone deacetylase 1 (HDAC1) complexes represents a novel strategy to induce directed neuronal fate.
• This approach offers a promising non-cytotoxic therapeutic avenue for treating malignant gliomas by targeting GSCs.